Compare Raymond James Financial, Inc. (RJF) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Tango Therapeutics Inc. — how do they compare? Raymond James Financial, Inc. trades at $156.93 (market cap $30.15B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Raymond James Financial, Inc. is far larger — about 8× Tango Therapeutics Inc.'s market cap, and Raymond James Financial, Inc. pays a 1.38% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 75 Days and Tango Therapeutics Inc. for 0 Days on average.
| RJF | TNGX | |
|---|---|---|
Market Cap | $30.15B | $3.75B |
Volume | 980,106 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $181.18 | $32.90 |
52-Week Low | $140.89 | $7.50 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $24.02B | $2.77B |
Dividend Yield | 1.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $157.25, down 0.88% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with consistent earnings beats, revenue growth from $10.9B in 2022 to $13.84B in 2025, and robust profitability margins. Recent news highlights executive leadership changes and a declared $0.54 dividend payable in October 2026.
The stock presents a mixed outlook: attractive valuation multiples and analyst consensus price target of $178.50 suggest upside potential, but bearish technical indicators and rising expenses pose near-term risks. Investment appeal hinges on sustained earnings growth and management's execution amid market volatility.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
